These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 14570767

  • 1. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD.
    Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
    [Abstract] [Full Text] [Related]

  • 2. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X, Wang JS, Neuvonen PJ, Backman JT.
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [Abstract] [Full Text] [Related]

  • 3. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT.
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [Abstract] [Full Text] [Related]

  • 4. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [Abstract] [Full Text] [Related]

  • 5. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
    Machinist JM, Mayer MD, Shet MS, Ferrero JL, Rodrigues AD.
    Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
    Kim JH, Kwon SS, Jeong HU, Lee HS.
    Int J Mol Sci; 2017 May 01; 18(5):. PubMed ID: 28468305
    [Abstract] [Full Text] [Related]

  • 7. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A, Kenny JR, Grime K.
    Drug Metab Dispos; 2005 Nov 01; 33(11):1637-47. PubMed ID: 16049126
    [Abstract] [Full Text] [Related]

  • 8. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY, Chen C, Yang Z, Rodrigues AD.
    Drug Metab Dispos; 2009 Aug 01; 37(8):1667-75. PubMed ID: 19454483
    [Abstract] [Full Text] [Related]

  • 9. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
    Karjalainen MJ, Neuvonen PJ, Backman JT.
    Drug Metab Dispos; 2006 Dec 01; 34(12):2091-6. PubMed ID: 16985100
    [Abstract] [Full Text] [Related]

  • 10. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA, Tjia JF, Back DJ.
    Br J Clin Pharmacol; 1998 Feb 01; 45(2):107-14. PubMed ID: 9491822
    [Abstract] [Full Text] [Related]

  • 11. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, Sawada Ji J.
    Drug Metab Dispos; 2002 Apr 01; 30(4):391-6. PubMed ID: 11901092
    [Abstract] [Full Text] [Related]

  • 12. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes.
    Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K.
    Drug Metab Dispos; 1999 Aug 01; 27(8):860-5. PubMed ID: 10421611
    [Abstract] [Full Text] [Related]

  • 13. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT, Chang YW, Lan SJ, Chen CT, Hsu JT, Yeh TK.
    Life Sci; 2006 Nov 25; 79(26):2432-40. PubMed ID: 16978661
    [Abstract] [Full Text] [Related]

  • 14. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
    Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T.
    Br J Clin Pharmacol; 1995 Apr 25; 39(4):421-31. PubMed ID: 7640150
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
    Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA.
    Drug Metab Dispos; 1998 Jul 25; 26(7):609-16. PubMed ID: 9660842
    [Abstract] [Full Text] [Related]

  • 16. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF.
    Drug Metab Dispos; 1997 Dec 25; 25(12):1407-15. PubMed ID: 9394031
    [Abstract] [Full Text] [Related]

  • 17. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH, Kwon MJ, Choi EJ, Zheng YF, Yoon KD, Liu KH, Bae SK.
    Chem Biol Interact; 2013 Sep 05; 205(1):11-9. PubMed ID: 23777987
    [Abstract] [Full Text] [Related]

  • 18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE.
    Drug Metab Dispos; 2001 Jan 05; 29(1):41-7. PubMed ID: 11124228
    [Abstract] [Full Text] [Related]

  • 19. In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin.
    Habenschus MD, Moreira FL, Lopes NP, de Oliveira ARM.
    Planta Med; 2017 May 05; 83(8):727-736. PubMed ID: 28073119
    [Abstract] [Full Text] [Related]

  • 20. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
    Yeung JH, Or PM.
    Phytomedicine; 2012 Mar 15; 19(5):457-63. PubMed ID: 22305191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.